OSCR
Oscar Health, Inc.
OSCR has the edge over STXS overall, supported by stronger fundamentals and stronger modeled upside.
STXS
Stereotaxis, Inc.
STXS has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STXS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
STXS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
STXS PE Valuation
STXS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect STXS's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STXS on earnings quality, reporting a profit while its opponent remains loss making.
STXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.24 | +$0.05 |
| Q1 2026 | -$0.24 | +$0.07 |
| Q4 2025 | -$0.25 | +$0.05 |
| Q3 2025 | -$0.28 | -$0.01 |
| Q2 2025 | -$0.29 | -$0.03 |
| Q1 2025 | -$0.31 | -$0.05 |
| Q4 2024 | -$0.30 | -$0.03 |
| Q3 2024 | -$0.27 | $0.00 |
STXS is still losing money, but less than at its worst: $0.24 per share over the past year, against $0.31 at its worst in early 2025.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over STXS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over STXS on profitability, with a higher operating margin.
STXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.7M | -13% |
| Q1 2026 | $6.3M | -16% |
| Q4 2025 | $8.6M | +36% |
| Q3 2025 | $7.5M | -19% |
| Q2 2025 | $8.8M | +95% |
| Q1 2025 | $7.5M | +8.6% |
| Q4 2024 | $6.3M | +39% |
| Q3 2024 | $9.2M | +18% |
STXS's revenue has slid since its 2024 peak: $8M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -60% | -14 points |
| Q1 2026 | -95% | -16 points |
| Q4 2025 | -65% | +55 points |
| Q3 2025 | -88% | -19 points |
| Q2 2025 | -45% | +89 points |
| Q1 2025 | -79% | -10 points |
| Q4 2024 | -120% | -4.1 points |
| Q3 2024 | -69% | +3.3 points |
STXS's operating margin was −60% last quarter, down 14 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with STXS at down 101%.
STXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | -$1.7M |
| Q4 2025 | -$4M | -420% |
| Q3 2025 | -$4.2M | +$135K |
| Q4 2024 | $1.3M | +$3.7M |
| Q3 2024 | -$4.3M | -$3.4M |
| Q4 2023 | -$2.4M | +$482K |
| Q3 2023 | -$977K | +$1.8M |
| Q2 2023 | -$2.9M | -$1.2M |
STXS has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | +14% | +12.1M shares |
| 3 years | +23% | +19M shares |
| 5 years | +32% | +24.5M shares |
| Available history | +56% | +35.7M shares |
STXS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STXS Net Leverage
STXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 18.5 | Oversold |
STXS's weekly RSI is 31 (neutral) and its Stochastic is 18 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STXS PE vs Healthcare Sector
STXS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STXS on trend strength, trading above more of its moving averages.
STXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 19% below |
| 20 week MA | $1.28 | 34% below |
| 50 week MA | $1.76 | 52% below |
| 100 week MA | $2.05 | 59% below |
| 200 week MA | $2.02 | 58% below |
STXS is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STXS on returns for 2026, with the stronger performance.
STXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $5.14 | +2.2% |
| 2021 | $5.14 | $6.26 | +22% |
| 2022 | $6.26 | $2.03 | -68% |
| 2023 | $2.03 | $1.75 | -14% |
| 2024 | $1.75 | $2.29 | +31% |
| 2025 | $2.29 | $2.46 | +7.4% |
| 2026 YTD | $2.46 | $0.85 | -65% |
STXS is down 65% so far in 2026, after finishing higher in four of the previous six years.